Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - factor viii (antihaemophilic factor), von willebrand factor human - pdr+solv for soln for inj - 1000/1000 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma limited - factor viii (antihaemophilic factor), von willebrand factor human - pdr+solv for soln for inj - 500/500 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

bio products laboratory limited - factor viii (antihaemophilic factor), von willebrand factor - pdr+solv for soln for inj - 250 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

bio products laboratory limited - factor viii (antihaemophilic factor), von willebrand factor - pdr+solv for soln for inj - 500 international unit - blood coagulation factors

Ireland - English - HPRA (Health Products Regulatory Authority)

bio products laboratory limited - factor viii (antihaemophilic factor), von willebrand factor - pdr+solv for soln for inj - 1000 international unit - blood coagulation factors

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 1000 iu; von willebrand factor, quantity: 2400 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - von willebrand factor, quantity: 800 iu; factor viii, quantity: 900 iu; factor viii, quantity: 15 mg - injection, powder for - excipient ingredients: calcium chloride dihydrate; glycine; sodium chloride; sucrose; octoxinol 9; tributyl phosphate; sodium citrate dihydrate - 1. von willebrand disease (vwd): treatment of bleeding episodes including surgical bleeding in patients with von willebrand's disease when desmopressin treatment is ineffective or contraindicated. 2. haemophilia a: treatment and prophylaxis of bleeding including surgical bleeding in patients with haemophilia a (congenital fviii deficiency). there are insuffcient data to recommend the use of wilate in children less than 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - von willebrand factor, quantity: 400 iu; factor viii, quantity: 7.5 mg; factor viii, quantity: 450 iu - injection, powder for - excipient ingredients: tributyl phosphate; sucrose; sodium citrate dihydrate; sodium chloride; calcium chloride dihydrate; octoxinol 9; glycine - 1. von willebrand disease (vwd): treatment of bleeding episodes including surgical bleeding in patients with von willebrand's disease when desmorpressin treatment is effective or contraindicated. 2. haemophilia a: treatment and prophylaxis of bleeding including surgical bleeding in patients with haemophilia a (congenital fviii deficiency). there are insifficient data to recommend the use of wilate in children less than 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 500 iu; von willebrand factor, quantity: 1200 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor viii, quantity: 250 iu; von willebrand factor, quantity: 600 iu - injection, diluent for - excipient ingredients: - the prophylaxis and treatment of non-surgical and surgical bleeding in patients with von willebrand disease when desmopressin (ddavp) treatment is ineffective or contraindicated. the prophylaxis and treatment of non-surgical and surgical bleeding associated with factor viii deficiency due to haemophilia a.